title: Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone.
abstract: BACKGROUND
  Adenoid cystic carcinoma (ACC) of the salivary gland frequently develops lung metastases. In cases in which chemotherapy is indicated, resistance is a common phenomenon. New drugs, such as cetuximab, have been chosen to avoid this chemoresistance.
  
  
  RESULTS
  A 54-year-old man was diagnosed with ACC of the right submandibular gland. He underwent a submandibular gland resection with adjuvant radiotherapy. Three years later, bilateral lung metastases were diagnosed and treated with various chemotherapy schedules, including paclitaxel without success. We obtained radiographic response, followed by disease stabilization for more than 1 year with the addition of cetuximab to paclitaxel administered at low weekly doses (metronomic schedule).
  
  
  CONCLUSIONS
  This case demonstrates for the first time a reversion of primary resistance to chemotherapy in ACC that is currently considered chemoresistant by use of a combination of metronomic chemotherapy with new targeted agents such as cetuximab. Metronomic chemotherapy was also well tolerated and achieved long-term response.
authors.affiliation: Otorhinolaryngology Department, University of Barcelona. Hospital Clínic. IDIBAPS (Augusto Pi Sunyer Institute for Biomedical Research), Barcelona, Spain. mcaba@clinic.ub.es
authors.forename: Miguel
authors.initials: M
authors.lastname: Caballero
authors.forename: Aaron
authors.initials: A
authors.lastname: E Sosa
authors.forename: Andrea
authors.initials: A
authors.lastname: Tagliapietra
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Grau
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001707:Biopsy, Needle; D003528:Carcinoma, Adenoid Cystic / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D000068818:Cetuximab; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D012468:Salivary Gland Neoplasms / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D000068818:Cetuximab